ArticleBMC cancer2026
Sequential thoracic radiotherapy following immunotherapy in advanced non-small cell lung cancer: a real-world retrospective cohort study on efficacy and safety.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundImmunotherapy (IO) plays a pivotal role in treating advanced non-small-cell lung cancer (NSCLC). However, its effectiveness in achieving local control remains suboptimal. In contrast, consolidation radiotherapy offers distinct advantages for local disease management. Nevertheless, evidence regarding the efficacy and safety of sequential thoracic radiotherapy (TRT) following systemic IO in patients with advanced NSCLC is still limited.
methodsThis single-center, retrospective cohort study enrolled 62 eligible patients with advanced NSCLC. All patients received either IO monotherapy or chemotherapy combined with IO, followed by sequential TRT. We analyzed progression-free survival (PFS), overall survival (OS), treatment response, and adverse events. Survival outcomes were calculated from the initiation of IO.
resultsThe median PFS and OS were 9 months and 15 months, respectively. Treatment responses varied: five patients (8.06%) achieved a complete response (CR), 36 (58.06%) a partial response (PR), 19 (30.65%) had stable disease (SD), and two (3.23%) experienced progressive disease (PD). Patients who achieved CR or PR after IO demonstrated significantly longer PFS and OS compared to those with SD or PD (median PFS: 11.00 vs. 7.00 months, hazard ratio (HR): 0.45, 95% confidence interval (CI): 0.22–0.91, P < 0.001; median OS: not reached vs. 8.00 months, HR: 0.29, 95% CI: 0.13–0.67, P < 0.001). The treatment-related adverse events were manageable, with a low incidence of high-grade radiation pneumonitis (0%) and esophagitis (0%).
conclusionsThe sequential administration of TRT after IO in patients with advanced NSCLC demonstrated potential feasibility in delaying disease progression and showed encouraging survival signals, with a manageable toxicity profile. However, these findings are constrained by the study’s retrospective design and necessitate validation through prospective controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.